Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

HeartSciences Inc. - Warrant (NQ: HSCSW )

0.0400 UNCHANGED
Last Price Updated: 1:57 PM EST, Dec 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HeartSciences Inc. - Warrant

< Previous 1 2 Next >
HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Signs Distribution Agreement with FJ Medical, Denmark
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences’ MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio
European Patent Allowed for Quantification by an ECG of Key Heart Measures using AI 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
MyoVista wavECG goes into clinical use at the Naya Imaging Center in Denmark
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Named as a Top 10 Healthcare Artificial Intelligence Solutions Provider 2023 by Healthcare Tech Outlook Magazine
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Participate at the Inaugural EF Hutton Global Conference
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Participate in The Benchmark Company’s Virtual Individual Investor Healthcare Conference
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Present at the Planet MicroCap Showcase: VEGAS 2023
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2023 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences CEO Invited as Featured Guest on The Big Biz Show, February 7 at 11:45 a.m. Pacific Time
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Granted Key Israeli International Patent for its MyoVista® Wavelet Technology Utilizing Artificial Intelligence (AI) for Early Detection of Heart Disease
Israeli patent covers a country known as a hotbed for medical device innovation 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Further Internationalization of its Patent Portfolio
Granted Korean Patent for its MyoVista® Wavelet Technology 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
Correction: HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Appoints David R. Wells to its Board of Directors, an Experienced Capital Markets and Finance Executive
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2023 Financial Results
Patient Enrollment Close to Completion and Continue to Target FDA De Novo Resubmission Around Current Fiscal Year End 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences and Rutgers University Announce Multi-Year Collaboration to Develop AI-based ECG Algorithms
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Present at the 2022 RHK Disruptive Growth Conference on December 5, 2022
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences’ MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events
Independent study demonstrates novel AI-ECG algorithm could provide a cost-effective strategy for improving cardiac risk stratification 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista® ECG
Patent builds on previously granted U.S. patent as well as strengthens and diversifies the IP portfolio and further protects future revenues 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Named as a Top 10 MedTech Startup 2022 by MedTech Outlook Magazine
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Present at MicroCap Rodeo's Windy City Roundup Conference on October 12th
Via ACCESSWIRE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.